Clinical Trial Update: Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions [Phase 2]

View source ↗

Summary

A Phase II randomized, placebo-controlled trial is being conducted to evaluate intralesional nivolumab for high-risk oral premalignant lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Premalignant Lesions

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Premalignant Lesion | Phase 2 | Status: RECRUITING